Project description
Foetal-inspired regenerative treatment for low back pain
Low back pain (LBP) affects nearly 80 % of the population and is caused by intervertebral disc degeneration. Current treatments are costly, invasive, and often ineffective, impacting patients' quality of life. The EU-funded FETALIX project aims to introduce a novel biomaterial that will revolutionise LBP treatment and rejuvenate the spine. The regenerative biomaterial has been inspired by foetal tissue and promises to improve clinical outcome at a lower cost, promoting circular economy. Its use can be extended to dogs, who might also suffer from intervertebral disc degeneration. Project funding will ensure readiness to conduct clinical testing of this innovative biomaterial and introduce it to the market.
Objective
Joana Caldeira is a forward-thinking researcher, PhD in Biomedicine and FETALDISC’s CEO, whose passion is to contribute to the generalized life quality improvement of an increasingly ageing society. Following her expertise as a researcher in the field of extracellular matrix modulation, improving current regenerative therapies, namely intervertebral disc disease, Joana was faced with a problem that is many times overlooked: Low Back Pain (LBP). Although it may pose as a straightforward health condition to address, LBP, frequently caused by intervertebral disc degeneration (IVDD), affects up to 80% of the population, having a tremendous socioeconomic impact. This condition often requires expensive, lengthy, and invasive treatment, which rarely treats the underlying disease, impacting patient’s life quality by affecting mobility, ability to work and sleep. Moreover, this health challenge is also prevalent in the canines, with many breeds suffering from continuous pain, limited mobility, and immobilization at older ages. To address this challenge, Joana founded FETALDISC, LDA to mainstream innovative, and sustainable deep tech biomedical solutions, especially for IVDD treatment, having FETALIX as its core product – THE FIRST REGENERATIVE FETAL-INSPIRED BIOMATERIAL TO TREAT LBP. The solution will change the market dynamics, by achieving better intervertebral disc regenerative results, being more affordable and eliminating existing treatments setbacks. The company’s biggest challenge is to master business and market insights to track investors’ interest, undertake clinical trials, and certification, and thus launch FETALIX into the market. Women TechEU support will be paramount for the company’s business and market robustness, as well as its scale-up through consolidating its business model and plan, thus allowing the company to be fully prepared for the commercialization stage. Women TechEU will be part of the journey of REJUVENATING THE SPINE TO SET PATIENTS FREE.
Keywords
Programme(s)
- HORIZON.3.2 - European innovation ecosystems Main Programme
Funding Scheme
HORIZON-CSA - HORIZON Coordination and Support ActionsCoordinator
4250-455 Porto
Portugal
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.